Principles in the design of ligand-targeted cancer therapeutics and imaging agents

Madduri Srinivasarao, Chris V. Galliford, Philip Low

Research output: Contribution to journalArticlepeer-review

386 Scopus citations

Abstract

Most cancer drugs are designed to interfere with one or more events in cell proliferation or survival. As healthy cells may also need to proliferate and avoid apoptosis, anticancer agents can be toxic to such cells. To minimize these toxicities, strategies have been developed wherein the therapeutic agent is targeted to tumour cells through conjugation to a tumour-cell-specific small-molecule ligand, thereby reducing delivery to normal cells and the associated collateral toxicity. This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of ligand-drug conjugates and ligand-imaging-agent conjugates that are currently in development.

Original languageEnglish (US)
Pages (from-to)203-219
Number of pages17
JournalNature Reviews Drug Discovery
Volume14
Issue number3
DOIs
StatePublished - Mar 4 2015

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Principles in the design of ligand-targeted cancer therapeutics and imaging agents'. Together they form a unique fingerprint.

Cite this